

PubMed

U.S. National Library of Medicine
National Institutes of Health



Display Settings: Abstract

[Autoimmunity](#). 2005 Mar;38(2):123-37.

IVIg therapy in autoimmunity and related disorders: our experience with a large cohort of patients.

Shoenfeld Y, Katz U.

Center for Autoimmune Diseases, Department of Internal Medicine B, Sheba Medical Center, Tel-Hashomer, Ramat Gan 52621, Israel. shoenfel@post.tau.ac.il

Intravenous immunoglobulin (IVIg) is used to treat a number of immune-deficiencies and autoimmune diseases. It has been shown that IVIg contains anti-idiotypic antibodies, which explains its immunomodulatory action. In murine models, recent investigations have demonstrated that IVIg can prevent and reduce the affliction by systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS) and scleroderma. Relevant disease-specific fractions of IVIg were able to reproduce and even enhance the therapeutic effect in a murine model. IVIg treatment before tumor resection in rodents inoculated with melanoma and sarcoma cells dramatically improved the cure rate (50%) in comparison to the control group (0%). In patients affected by SLE, several clinical manifestations responded to IVIg treatment including serositis, hematological manifestations, treatment-resistant nephritis and central nervous system involvement. Similarly, in women with recurrent fetal loss due to APS, IVIg was able to diminish the abortion rate. Vasculitides such as Churg-Strauss' and Wegener's and skin fibrosis in patients affected by scleroderma improved after IVIg treatment. In agreement with in vitro investigations, prolonged survival has been noted in cancer patients treated with IVIg. We suggest that in the presence of a steroid and immunosuppressive-resistant autoimmune disease, IVIg is a rational and safe choice.

PMID: 16040333 [PubMed - indexed for MEDLINE]

[Publication Types](#), [MeSH Terms](#), [Substances](#)

[LinkOut - more resources](#)